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Summary.-Three hundred and seventy-two patients were randomized between 3
regimens of chemotherapy: cyclophosphamide, intermittent melphalan, and mel-
phalan with prednisone, and were followed up to death or for at least 5 years. There
was no difference in survival between the treatments, either overall or in anysubgroup
of patients. Therefore, the choice among these 3 treatments should be guided by the
patient's comfort and convenience.
The most important prognostic feature at presentation was the quality of renal
function. It was possible to define good, intermediate and poor renal-function groups
which were highly correlated with prognosis (X2 for trend=62-6). The haemoglobin
level at presentation was strongly correlated with prognosis among patients in the
good renal-function group. Among 107 patients who presented with good renal func-
tion and with haemoglobin above 100 g/l, the 5-year survival was 43%o. Other prog-
nostic features were much less important when account was taken of renal function
and haemoglobin level.
IN THE Medical Research Council's
First Myelomatosis Trial, previously un-
treated patients were randomly allocated
to receive daily oral cyclophosphamide or
melphalan. By August 1968, when 276
patients had been entered into the first
trial, there was no significant difference in
survival between the two groups (MRC,
1971). During the course of that trial it
was claimed by others that intermittent
melphalan was more effective than con-
tinuous administration, and that the
addition of prednisone to intermittent
melphalan gave further benefit (Bergsagel
et al., 1967; Alexanian et al., 1969). The
MRC's Second Myelomatosis Trial, which
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we now report, was therefore started to
compare cyclophosphamide at the same





orally at a daily dose of 150 mg or, if
neutropenia or thrombocytopenia de-
veloped (see below) at the highest tolerated
dose.
Intermittent melphalan was adminis-
tered in a short 4-day course and subse-
quent 7-day courses. First course: 10 mg
daily for 4 days. If the blood urea con-MRC WORKING PARTY ON LEUKAEMIA IN ADULTS
centration (BUC) was over 13 3 mm,
treatment was delayed until the patient
had been adequately hydrated, and then
5 mg was given daily for 4 days. Second
and subsequent courses: 10 mg daily for
7 days or 5 mg daily for 7 days ifBUC still
exceeded 13 3 mm, reduced to 3-5 days if
it considerably exceeded 13 3 mm.
The interval between courses was
usually 6-8 weeks, depending on the
trends in the neutrophil and platelet
counts. Treatment was deferred or re-
duced if the neutrophil count remained
below 2-5 x 109/1 and/or the platelet count
remained below 100 x 109/1.
Intermittent melphalan andprednisone.
Melphalan was administered intermit-
tently as above, each daily dose being
accompanied by 40 mg of prednisone.
After the end of each course of melphalan,
30, 20, 15, 10 and 5 mg ofprednisone were
given on successive days.
On all 3 regimens, radiotherapy (except
for relief of pain), androgens, oestrogens
and anabolic steroids as supportive
therapy were to be avoided unless chemo-
therapy alone proved inadequate. Blood
transfusions and analgesics could be used
as required.
Eligibility for entry to the trial
Patients with myelomatosis were not
considered eligible unless abnormal plasma
cells had been identified in marrow films
or sections and, in addition, characteristic
skeletal lesions had been demonstrated
radiologically, and/or characteristic pro-
tein changes had been found in the serum
or urine. Patients who had previously
received urethane or cytotoxic treatment
were ineligible. Previous local irradiation
of a single painful site, or temporary
irradiation for not more than 3 weeks, or
administration of adrenal corticosteroids
for the treatment ofacute hypercalcaemia,
or previous administration of androgens,
oestrogens or anabolic steroids, did not
preclude admission to the trial. Eligible
patients were randomized to one of the 3
treatment schedules by telephone to the
Leukaemia Trials Office in London.
STATISTICAL METHODS
These are as described in the report on
statistical methods to the Medical Research
Council's Leukaemia Steering Committee
(Peto et al., 1976. 1977). They chiefly involve
the plotting of Kaplan-Meier life-table esti-
mates of the percentages of patients alive at
various times up to 5 years after entry to
illustrate various patterns of survival, and
the calculation of logrank P-values to test
the statistical significance of any apparent
differences in survival. For the latter, exact
variance calculations were made (ibid.,
Statistical Note 7) and continuity corrections
were not used (ibid., p. 38). Chi-square values
without subscripts are for the trend statistic
unless otherwise stated, and therefore have
only one degree of freedom.
DATA COLLECTED
BetwN-een September 1968 and May 1975,
383 patients from 19 centres were randomized
by telephone, but for 11 of these, repeated
subsequent requests for data failed to locate
a record ofany such patient. Ofthe remaining
372, 124 were allocated to receive cyclo-
phosphamide, 128 melphalan alone and 120
melphalan with prednisone. All but 2
patients were followed up to death or for at
least 5 years (until 31 December 1979). These
2 were last known to be alive 3 and 21 months
after entry respectively, and it has not been
possible to trace them further. Whenever a
patient died, the date of death was recorded
and the cause of death sought.
The following information was requested
on presentation: sex, age, serum albumin,
calcium, IgM, alkaline phosphatase, BUC and
haemoglobin levels, platelet and leucocyte
counts, and serum paraprotein levels. Urine
was collected for paraprotein type (heavy and
light chain) and the concentrations of Bence-
Jones protein (BJP) and high-mol.-wt pro-
teins (HMWP, of higher molecular weight
than BJP). Radiological screening for lytic
lesions, pathological fractures or vertebral
wedging was also requested. Information on
whether the BUC related to a pre- or post-
hydration sample wias not specifically sought.
During the first few weeks of therapy a
clinical assessment of renal function was re-
corded in the following categories: "out of
control". "no reason at all to suspect any
impairment" or "other". Three months after
randomization, the serum paraprotein level
was again recorded.
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TABLE I.-Relative death rates according to blood urea concentration (BUC) and concentra-





> 14-0 1-86 (19)
Total 0-80
X2 for
HMWP (g/1) trend with
A respect to
0.1-0-99 > 1.0 Total HMWP
0-80 (63) 1-87 (17) 0 73 12-16
(P< 0-001)
1-33 (49) 1-17 (31) 1-18 0-25
(NS)
1-79 (31) 1-65 (26) 1-75 0 09
(NS)
1-07 1-42 1.00 14-69
(P < 0-001)
Numbers of patients in parentheses. The relative death rate for a cell of the table is the ratio of the
observed number of deaths to that expected from the extent of exposure to risk of death experienced by
patients in that cell.
NS =not significant.
The immunoglobulins in the serum and
urine were estimated in one central laboratory
by cellulose-acetate electrophoresis and typed
by electrophoresis (Hobbs, 1967). The radio-
logical findings were abstracted from local
skeletal surveys of the skull, axial skeleton
and long bones.
RESULTS
In addition to the effects of the 3 treat-
ments on survival, the various presenta-
tion features recorded for all 372 patients
were considered in relation to prognosis.
For those patients on whom the relevant
data were available, other features also
considered were the serum levels of
albumin, IgM, paraprotein and calcium,
the paraprotein type and urinary BJP and
HMWP concentration.
Effect of treatment on survival
There was no apparent difference in
survival between the 3 treatment sched-
ules (X2=0'09, Fig. 1). Overall, the
median length of survival was 20 months
from the date of randomization.
Renalfunction
The strongest determinants of prog-
nosis in patients with myelomatosis have
been shown to be those indicating renal
impairment, namely elevated BUC and
excessive amounts ofHMWP in the urine.
The former is an indicator of a reduced
... .....
FI 1.Duration of survival for patients
randomized to receive cyclophosphamide
(A), meiphalan (B) or melphalan with pred-
nisone (C). Numbers of patients in paran-
theses.
rate ofglomerular filtration, and the latter
of glomerular damage. Table I shows the
relationship between these 2 indices and
prognosis. Among patients whose blood
urea was high (BUC £ 7-0 mm) the pre-
sence or absence of HMWI in the urine
was of little or no prognostic significance.
However, among patients whose blood
urea was normal at presentation, those
having HMWP in the urine faired consider-
ably worse than those who did not (X2 =
12r16o Pc0 l001). The blood urea and
urinary proteins are objective laboratory
measurements, but are subject to con-
siderable uncertainty (not least because
they were sometimes recorded before, and
sometimes after, the hydration of the
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No. (%) whose renal function was:
r-
Good Uncertain Poor Total
5 (9) 28 (53) 20 (38) 53
33 (28) 49 (42) 36 (31) 118
107 (53) 56 (28) 38 (19) 201
145 (39) 133 (36) 94 (25) 372
~~~3 4-
FIG. 2.-Duration of survival for patients
according to renal function at randomiza-
tion (see text for the definition of these 3
categories). Numbers of patients in paren-
theses.
patient, and there is no reliable record of
the timing). Therefore, we also asked the
clinician to record at entry an impression
of the renal condition (see above). Not
surprisingly, this clinical impression was
ofstatistically significant assistance in pre-
dicting mortality, even among patients
who were still normal in terms of blood
urea and urinary proteins. It was, there-
fore, possible to define a composite vari-
able which more accurately reflected renal
function in relation to survival by dividing
patients into 3 groups:
(a) Good renal function; blood urea
< 7 0 mM, <1I0 g/l (if measured) of
HMWP in the urine and "no reason
at all to suspect any renal impair-
ment" (145 patients).
(b) Uncertain renal function; those not
in (a) or (c) (133 patients).
(c) Poor renal function; blood urea
> 14-0 mm or renal function described
as "out of control" (94 patients).
The survival curves for these 3 renal-
function groups are shown in Fig. 2 (x2 =
62.6). This 3-value composite variable will
be used in the rest ofthe analyses to allow
for the effect of renal impairment in the
assessment oftheotherprognostic features.
Anaemia
The relationship between haemoglobin
value at presentation and prognosis was
highly significant statistically (X2 =21 1).
Much of this was due to the strong corre-
lation of haemoglobin concentration with
renal function (Table II). Only 9% of
patients with a low haemoglobin (< 75 g/l)
had good renal function, whereas 53% of
those with a high haemoglobin ( > 100 g/l)
had no indication of renal damage. When
allowance was made for renal function in
the analysis, a definite effect of haemo-
globin level on survival was present only
in patients with good renal function
(x2 = 7 3; P <0X01; see Fig. 3) and not at
all in the other two renal-function cate-
gories (x2= 0X6 and 0X1 respectively).
There were 107 patients (29% of those in
the study) who had both good renal func-
tion and haemoglobin level > 100 g/l. The
median length of survival for these
patients was 55 months.
In the third myeloma trial (MRC, 1980)
it was found that clinical performance at
presentation ("asymptomatic or minimal
symptoms" versus "restricted activity or
bedridden") was related to prognosis
independently of BUC and haemoglobin.
Z , E ,;;)T,4
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FIG. 3.-Duration of survival for patients
with good renal function according to their







Information on initial clinical performance
was not explicitly requested in the second
trial, but it could be estimated for 330 of
the 372 patients by reviewing their
records. With this retrospective approach
it was possible to confirm the importance
of initial clinical performance as a pre-
dictor of prognosis, even among patients
with apparently similar renal function and
haemoglobin level (x2=9 94, P=0-002,
for performance status restrospectively
stratified for renal function groups and
haemoglobin levels).
Treatment among patients with normal
haemoglobin (> 100 g/l) and good renal
function
Because of the overriding effect of im-
paired renal function on prognosis, any
real benefits of a treatment which effect-
ively reduced the total tumour-cell mass
might be obscured by irreversible renal
damage. The apparent lack of difference
between the 3 treatments (as shown in
Fig. 1) might have arisen because real but
small differences between the 3 treatments
were overshadowed by the effects of renal
damage. To discover whether there were
treatment differences among patients
whose disease was uncomplicated by such
features, we have therefore compared the
results for the 107 patients with good
renal function and haemoglobin level of
F~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~I
)'~~~~~~~ "
FIG. 4. Duration of survival for patients
with good renal function and haemoglobin
level > 100 g/l, according to treatment:
(A) cyclophosphamide, (B) melphalan and
(C) melphalan with prednisone. Numbers
of patients in parentheses.
> 100 g/l. However, there was still no
evidence of any material difference be-
tween the 3 treatments (Fig. 4).
Bence Jones proteinuria (BJP)
The presence of BJP was strongly
correlated with poor prognosis (X2 = 27.9),
but again this was in part due to the fact
that heavy BJP was usually associated
with impaired renal function. When the
effects of BJP were examined within
separate categories of patient, the only
patients among whom it was prognostic-
ally important were those with good renal
function and normal (> 100 g/l) haemo-
globin. The relationship ofBJP to survival
among patients with good renal function
is illustrated in Fig. 5(a) (x2 = 13X2,
P < 0.005).
M-immunoglobulin
A very strong association was found
between serum IgM level and prognosis
C..
FIG. 5.-Duano srivl fortpatients
.. p1 t ;n .
FIG -. 5 . Duato of suvia fo patients.
with good renal function according to levels
of (a) urinary BJP or (b) serum IgM
Numbers of patients in parentheses
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(X2=2-263). This effect was clearlv present
in the good renal-function groups (X2 =
20.2); Fig. 5(b); less definitely present in
the uncertain renal-function group (x2=
4 6, P < 0.05) and absent in those with
poor renal fuinction (X2 < 0-01). Among the
87 patients with good renal function and
haemoglobin level > 100 g/l who had
IgM measurements, the group of 33 with
IgM > 0 30g/l had a death rate 36% ofthat
in the group with IgM concentration
< 0 3g/l.
Age
Younger patients had markedly better
life expectancy (x2=31.0). This was be-
cause of poorer renal function in older
patients, but within each of the 3 renal-
function groups there was some residual
effect of age (X2=4 1a 7 4 and 2.4) which
is not surprising since the period offollow-
up constitutes a substantial fraction ofthe
remaining life expectancy of the older
patients.
The effects of renal function on the
relationship between prognosis and haemo-
globin, BJP, IgM and age are summarized
in Table III.
Paraproteins
The level ofparaprotein in the serum (of
patients without BJP myeloma) bore no
relationship to prognosis for IgG patients,
but among IgA patients there was a non-
significant tendency for those with higher
paraprotein concentrations to die earlier.
The observation arising from the 1st MRC
trial (1973) that patients whose serum
paraprotein level fell slowly during treat-
ment did better than those whose level
decreased rapidly, was not confirmed. In
the present trial, faster responders fared
better than slow responders, and better
than those who did not respond at all,
though the differences were not statistic-
ally significant.
Of the 354 patients whose paraprotein
type was recorded, 39 (Il %) had BJP and
no monoclonal heavy chain, 102 (29%)
had IgA, 207 (580o) had IgG8, and 6 (20o)
had IgD. Overall there was no statistically
significant correlation of type with sur-
vival, but among patients whose para-
protein level was raised ( > 40 g/l for IgG
and > 30 g/l for IgA) those with IgA had a
worse prognosis than those with IgG
(X2 = 3-88, P <0.05). Patients with only
BJP presented on average with more BJP
in their urine (4.46 g/l) than patients who
also had IgA or Ig( (l 15 g/l) and a
slightly higher mean BUC (10.6 vs 101
mM). In contrast with the 1st MRC
Myeloma Trial (Hobbs, 1969) the fre-
quency of lytic lesions and hypercalcaemia
was similar in all types of myeloma.
Fifty-three percent (185/352) ofpatients
whose light-chain type could be deter-
mined had Type K light chains, but light-
chain type was unrelated to prognosis.
Within groups of patients of each heavy-
chain type, those patients with Type A
light chains had a higher urinary BJP
concentration (overall mean 2-05 g/l com-
pared with 1P05 g/l for Type K myelomas)
and a higher BUC (I 1P95 mM compared
wlTith 8 63 mm for Type K myelomas). In
contrast with the 1st MRC Trial patients
with poor renal function who excreted
Type A light chains did no better than
those excreting Type K light chains. The
suggestion that patients who excrete Type
K respond better to melphalan than those
who excrete Type A (Bergsagel et al., 1965;
Hobbs, 1969) was also not confirmed.
Otherfeatures
Platelet count and the levels of serum
albumin and alkaline phosphatase at pre-
sentation were independently related to
prognosis, to degrees which were statistic-
ally significant (x2= 10-7, 12*9 and 329
respectively) but each effect was reduced
when adjustment was made for renal
function (X2=5 8, 5X5 and 3 l respect-
ively). The only factor which retained
significance within a renal-function group
was the level of serum albumin in patients
with poor renal function. In all 3 renal-
function groups, patients with low platelet
counts tended to do worse than the others
during the first 12 months of treatment,
but thereafter their prognosis was similar.
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Fma. 6.-Duration of survival, according to
serum albumin level, in patients with (a)
good, (b) uncertain and (c) poor renal
function. (A) serum albumin <30 g/l,
(B) 31-39 g/l, (C) >40 g/l. Number of
patients in parentheses.
No other prognostic feature was statis-
tically significant when related to prog-
nosis, either overall or for patients with
good renal function. Furthermore, there
was no subgroup of patients defined by
prognostic features measured at pre-
sentation where a striking difference could
be found in the effects of treatment.
DISCUSSION
The present trial was designed to com-
pare 3 treatment schedules for myelo-
matosis, but has not demonstrated any
difference in length of survival between
the groups. Moreover, no difference could
be found within the most favourable group
of patients: those whose disease was un-
complicated by features, particularly ad-
vanced renal failure, that could not be
reversed by a reduction ofthe tumour-cell
mass. Treatment with 7-day courses of
melphalan at monthly intervals is gener-
ally accepted as better tolerated than
daily cyclophosphamide, but the addition
of prednisone gave no apparent improve-
ment in survival. However, preliminary
analysis of the trial suggested that
melphalan plus prednisone might be some-
what better, and this influenced the design
ofthe 3rd MRC Myelomatosis Trial (MRC,
1980) which compared intermittent high-
dose cyclophosphamide with intermittent
melphalan and prednisone for non-
azotaemic patients.
Analysis of the various radiological,
biochemical and haematological features
measured at presentation confirmed many
of the findings of the 1st MRC Myelo-
matosis Trial. The extent of renal dys-
function, measured by BUC and the con-
centration of HMWP in the urine as well
as by clinical assessment, again proved to
be the most important prognostic feature.
All other features were less important
when allowance was made for renal con-
dition. However, among patients without
renal dysfunction, other features such as
haemoglobin, urinary BJP, and serum
IgM level were useful (though interrelated)
indicators ofprognosis.
The cause of anaemia in myelomatosis
is not known. It may reflect the extent of
marrow infiltration by myeloma cells,
though the strength of the association of
haemoglobin level with longevity in this
and in the 3rd trial (MRC, 1980) greatly
exceeds the correlations between prog-
nosis and platelet or white-cell counts, and
suggests the existence of a more specific
mechanism. Alternatively, it may reflect
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an effect ofthe myeloma on iron utilization
or on some other aspect of marrow func-
tion, or even, in patients with apparently
unimpaired renal function, an occult effect
on the kidney which reduces erythro-
poiesis. In the 4th MRC Myelomatosis
Trial, which is just beginning, further
biochemical observations have been in-
cluded which may help to elucidate the
problem of anaemia and its strong rele-
vance to prognosis.
It is believed that BJP causes renal
damage, and that its level in the urine of
myeloma patients indicates the degree of
exposure to risk of damage. If so, our
results suggest that among patients who
have already developed poor or uncertain
renal function no substantial further
damage is done by BJP once treatment
has started. Among patients with appar-
ently good renal function, the results show
that BJP excretion is an indicator ofthose
at greatest risk regardless of treatment.
BJP among such patients might reflect
renal damage already present, but might
equally well indicate a continuing process
of damage. The existence of a small group
of 11 patients with poor renal function but
no detectable BJP in their urine seemed
anomalous (see Table III). However, when
9 of these were investigated further (the
records were missing for 2), 5 were
uraemic from infection, severe vomiting
and dehydration or longstanding kidney
disease, and a further 2 had normal ureas
after hydration. In only 2 was there no
explanation for the uraemia.
The subnormal concentrations of poly-
clonal (IgM) immunoglobulins in the
serum ofmyeloma patients are thought to
result from a suppressive effect on im-
munologically active cells exerted by the
myeloma cells. The magnitude ofthe effect
might then be expected to be proportional
to the total number or activity ofmyeloma
cells, and our finding of a progressive
worsening of the prognosis in patients
with successively declining serum IgM
concentrations is consistent with this.
In the 1st MRC Myelomatosis Trial
(MRC, 1973) the level of serum albumin
was found to be of important and inde-
pendent prognostic significance. In the
present trial it was found to be of much
less independent importance. Although
there was a fairly strong relationship
between albumin level and survival, this
was considerably reduced when allowance
was made for renal function (Fig. 6). The
remaining effect was in the same direction
as in the first trial but was not very sub-
stantial. One suggested explanation is that
in the first trial the albumin concentra-
tions were all estimated in a single labora-
tory by a single method, whereas in the
present trial each centre performed its
own albumin assays and different methods
were used. (Some centres used auto-
immunoprecipitation (AIP) but others
used electrophoresis, which carries the
risk that the presence of myeloma protein
might bias the estimation of the albumin
concentration.) In the 3rd Trial as well
(MRC, 1980) no statistically significant
relationship between initial albumin and
survival remained after adjusting for
other features. Consequently, it seems
most likely that albumin is less important
than we originally believed (MRC, 1973)
and that the strength ofthe correlation of
albumin with prognosis which we observed
in the 1st Trial was in part an artefact of
chance or of incomplete adjustment for
other factors.
It is possible to identify a group of
patients (those with good renal function
and Hb > 100 g/l) comprising almost one
third of those in the study, who have a
43% 5-year survival. Perhaps patients in
this group should receive more intensive
therapy (aimed at disease eradication)
since they are more likely to respond to
treatment, and renal failure is not an
immediate problem for them. Alternat-
ively, if all we can hope for is palliation,
patients with good prognosis may need
less cytotoxic therapy. In either case,
division of patients into 2-3 groups with
markedly different prognosis may be of
assistance in devising future trials.
We wish to thank the many colleagues who re-
ferred patients to the trial, and who provided the
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laboratory services for the trial, and Mrs V. Godwin
who prepared the typescript.
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